Artiva halts cell therapy after patient deaths, cuts 94% of staff
Summary
Artiva has made the decision to suspend its ongoing cell therapy clinical work following reported patient deaths. In addition to halting the treatment studies, the company is drastically reducing its workforce by laying off the vast majority of its employees.
Source: Read the full story at Stock Market News
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.